Results 241 to 250 of about 94,685 (278)

Digital Biomarkers for Precision Early Detection of Lung Cancer: Integrating AI‐Driven Multi‐Omics Into Clinical Pathways

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Lung cancer remains the leading cause of cancer‐related mortality worldwide, highlighting the urgent need for earlier detection within real‐world screening and patient management pathways. Recent advances in multi‐omics technologies have created new opportunities for identifying biomarkers associated with early‐stage lung cancer ...
Fan Bu, Zhi‐Qiang Ling
wiley   +1 more source

Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption

Comprehensive Physiology, Volume 16, Issue 1, February 2026.
Vildagliptin and omarigliptin, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have differential effects on bone cells. Although vildagliptin improved the bone microstructure of high‐fat diet‐fed rats, it was unable to downregulate osteoclastogenesis or the expression of key osteoclast transcripts.
Ratchaneevan Aeimlapa, Jiraporn Panmanee, Jarinthorn Teerapornpuntakit, Kannikar Wongdee, Jirawan Thongbunchoo, Nattapon Panupinthu, Saovaros Svasti, Nattayaporn Apaijai, Piangkwan Sa‐nguanmoo, Siriporn Chattipakorn, Nipon Chattipakorn, Narattaphol Charoenphandhu   +11 more
wiley   +1 more source

Proteomic Analysis of Regulated Dendritic Cell Endosomes Reveals Dynamic Adaptation to Antigen Uptake and Cross‐Presentation

European Journal of Immunology, Volume 56, Issue 2, February 2026.
Phagocytosis of yeast activates recruitment of proteases and trafficking factors from the secretory and endosomal pathways to the IRAP compartment and subsequently phagosomes, promoting cross‐presentation. In the absence of Sec22b, IRAP endosome and phagosome maturation to late endosomes is accelerated.
Alice Senni, Louise Grumbach, Sara Ceccacci, Mathieu Frechin, Nicolas Goudin, Ida Chiara Guerrera, Barbara Bertocci, Peter van Endert   +7 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cathepsin K and the Design of Inhibitors of Cathepsin K

Current Pharmaceutical Design, 2000
Cathepsin K, a cysteine protease of the papain family, was identified by sequencing complementary DNA libraries derived from osteoclasts. Cathepsin K can cleave bone proteins such as Type I collagen, osteopontin, and osteonectin. The localization and maturation of cathepsin K in activated osteoclasts have been characterized.
D S, Yamashita, R A, Dodds
openaire   +2 more sources

Human osteoblasts produce cathepsin K

Bone, 2006
Healthy bone is a rigid yet living tissue that undergoes continuous remodeling. Osteoclasts resorb bone in the remodeling cycle. They secrete H(+)-ions and proteinases to dissolve bone mineral and degrade organic bone matrix, respectively. One of the main collagenolytic proteinase in osteoclasts is cathepsin K, a member of papain family cysteine ...
Mandelin, J., Hukkanen, M., Li, T.F., Korhonen, M., Liljeström, M., Sillat, T., Hanemaaijer, R., Salo, J., Santavirta, S., Konttinen, Y.T.   +9 more
openaire   +3 more sources

Dipeptide nitrile inhibitors of cathepsin K

Bioorganic & Medicinal Chemistry Letters, 2006
A series of dipeptidyl nitriles as inhibitors of cathepsin K have been explored starting from lead structure 1 (Cbz-Leu-NH-CH2-CN, IC50 = 39 nM). Attachment of non-natural amino acid side chains in P1 and modification of the P3 subunit led to inhibitors with higher potency and improved pharmacokinetic properties.
Eva, Altmann, Reiner, Aichholz, Claudia, Betschart, Thomas, Buhl, Jonathan, Green, René, Lattmann, Martin, Missbach   +6 more
openaire   +2 more sources

New chemotypes for cathepsin K inhibitors

Bioorganic & Medicinal Chemistry Letters, 2008
Cyano pyrimidine acetylene and cyano pyrimidine t-amine, which belong to a new chemical class, were prepared and tested for inhibitory activities against cathepsin K and the highly homologous cathepsins L and S. The use of novel chemotypes in the development of cathepsin K inhibitors has been demonstrated by derivatives of compounds 1 and 8.
Naoki, Teno, Osamu, Irie, Takahiro, Miyake, Keigo, Gohda, Miyuki, Horiuchi, Sachiyo, Tada, Kazuhiko, Nonomura, Motohiko, Kometani, Genji, Iwasaki, Claudia, Betschart   +9 more
openaire   +2 more sources

Potent and selective cathepsin K inhibitors

Bioorganic & Medicinal Chemistry, 2006
A novel series of cathepsin K inhibitors derived from Novartis compound I is described. Optimization of the P1, P3, and P1' units led to the identification of 4-aminophenoxyacetic acid 24b with an IC(50) value of 4.8 nM, which possessed an excellent selectivity over other human cathepsins and good pharmacokinetic (PK) properties. Oral administration of
Tsuyoshi, Shinozuka, Kousei, Shimada, Satoshi, Matsui, Takahiro, Yamane, Mayumi, Ama, Takeshi, Fukuda, Motohiko, Taki, Yuko, Takeda, Eri, Otsuka, Michiko, Yamato, Shin-ichi, Mochizuki, Keiko, Ohhata, Satoru, Naito   +12 more
openaire   +2 more sources